GlassScriptPhysician profile
Parag Parekh
NPI 1013395979
$5,050.49
in general payments reported to CMS, 2019-2025
27 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $1,069 · 2023: $916 · 2024: $1,377 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,728 · Education: $44.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,727.70 |
| Education | $44.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $859.41 | 2021-2024 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $428.47 | 2022-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $425.68 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $387.70 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $384.04 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.31 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $258.73 | 2022-2025 | Ozempic, Rybelsus |
| Amgen INC. | $230.27 | 2024-2025 | Krystexxa, Tavneos, Parsabiv |
| Novartis Pharmaceuticals Corporation | $221.97 | 2023-2025 | |
| Horizon Therapeutics Plc | $174.25 | 2022-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $146.66 | 2022-2024 | Benlysta, Nucala |
| Shockwave Medical, INC | $132.56 | 2021 | |
| Akebia Therapeutics INC | $116.61 | 2023-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $113.28 | 2021-2024 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $109.37 | 2022-2025 | Terlivaz, Acthar |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $104.01 | 2022 | |
| Ani Pharmaceuticals, INC. | $95.72 | 2024-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $90.04 | 2022-2023 | Lupkynis |
| Ardelyx, INC. | $68.42 | 2024 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $67.03 | 2025 | |
| Opko Pharmaceuticals, LLC | $65.89 | 2022-2025 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $63.08 | 2023-2025 | Ultomiris |
| Daiichi Sankyo INC. | $49.16 | 2024-2025 | Injectafer |
| Lilly USA, LLC | $44.72 | 2024-2025 | Jardiance |
| Genzyme Corporation | $37.22 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $23.44 | 2022 | |
| Kyowa Kirin, INC. | $18.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parag Parekh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.